following a resubmission assessed under the end of life medicine process:
durvalumab (Imfinzi®) is accepted for use within NHSScotland.
Indication under review: In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
In an open-label phase III study durvalumab in combination with tremelimumab was associated with statistically significant improvements in overall survival compared with a multikinase inhibitor.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2857
- Indication:
In combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 10 November 2025